Cargando…

A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)

BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Hope, William W., El-Ghazzawy, Adel G., Winterstein, Brad A., Blatnik, Jeffrey A., Davis, S. Scott, Greenberg, Jacob A., Sanchez, Noel C., Pauli, Eric M., Tseng, Daniel M., LeBlanc, Karl A., Roberts, Kurt E., Bower, Curtis E., Parra-Davila, Eduardo, Roth, J. Scott, Deeken, Corey R., Smith, Eric F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689054/
https://www.ncbi.nlm.nih.gov/pubmed/34976385
http://dx.doi.org/10.1016/j.amsu.2021.103156
_version_ 1784618473405546496
author Hope, William W.
El-Ghazzawy, Adel G.
Winterstein, Brad A.
Blatnik, Jeffrey A.
Davis, S. Scott
Greenberg, Jacob A.
Sanchez, Noel C.
Pauli, Eric M.
Tseng, Daniel M.
LeBlanc, Karl A.
Roberts, Kurt E.
Bower, Curtis E.
Parra-Davila, Eduardo
Roth, J. Scott
Deeken, Corey R.
Smith, Eric F.
author_facet Hope, William W.
El-Ghazzawy, Adel G.
Winterstein, Brad A.
Blatnik, Jeffrey A.
Davis, S. Scott
Greenberg, Jacob A.
Sanchez, Noel C.
Pauli, Eric M.
Tseng, Daniel M.
LeBlanc, Karl A.
Roberts, Kurt E.
Bower, Curtis E.
Parra-Davila, Eduardo
Roth, J. Scott
Deeken, Corey R.
Smith, Eric F.
author_sort Hope, William W.
collection PubMed
description BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months. RESULTS: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m(2) received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm(2), mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence). CONCLUSION: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm(2) (43.3%) compared to defects <7.1 cm(2) (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes.
format Online
Article
Text
id pubmed-8689054
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86890542021-12-30 A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial) Hope, William W. El-Ghazzawy, Adel G. Winterstein, Brad A. Blatnik, Jeffrey A. Davis, S. Scott Greenberg, Jacob A. Sanchez, Noel C. Pauli, Eric M. Tseng, Daniel M. LeBlanc, Karl A. Roberts, Kurt E. Bower, Curtis E. Parra-Davila, Eduardo Roth, J. Scott Deeken, Corey R. Smith, Eric F. Ann Med Surg (Lond) Cohort Study BACKGROUND: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO). METHODS: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months. RESULTS: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m(2) received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm(2), mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence). CONCLUSION: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm(2) (43.3%) compared to defects <7.1 cm(2) (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes. Elsevier 2021-12-06 /pmc/articles/PMC8689054/ /pubmed/34976385 http://dx.doi.org/10.1016/j.amsu.2021.103156 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Cohort Study
Hope, William W.
El-Ghazzawy, Adel G.
Winterstein, Brad A.
Blatnik, Jeffrey A.
Davis, S. Scott
Greenberg, Jacob A.
Sanchez, Noel C.
Pauli, Eric M.
Tseng, Daniel M.
LeBlanc, Karl A.
Roberts, Kurt E.
Bower, Curtis E.
Parra-Davila, Eduardo
Roth, J. Scott
Deeken, Corey R.
Smith, Eric F.
A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title_full A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title_fullStr A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title_full_unstemmed A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title_short A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial)
title_sort prospective, multicenter trial of a long-term bioabsorbable mesh with sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (atlas trial)
topic Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689054/
https://www.ncbi.nlm.nih.gov/pubmed/34976385
http://dx.doi.org/10.1016/j.amsu.2021.103156
work_keys_str_mv AT hopewilliamw aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT elghazzawyadelg aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT wintersteinbrada aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT blatnikjeffreya aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT davissscott aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT greenbergjacoba aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT sancheznoelc aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT pauliericm aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT tsengdanielm aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT leblanckarla aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT robertskurte aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT bowercurtise aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT parradavilaeduardo aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT rothjscott aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT deekencoreyr aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT smithericf aprospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT hopewilliamw prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT elghazzawyadelg prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT wintersteinbrada prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT blatnikjeffreya prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT davissscott prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT greenbergjacoba prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT sancheznoelc prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT pauliericm prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT tsengdanielm prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT leblanckarla prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT robertskurte prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT bowercurtise prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT parradavilaeduardo prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT rothjscott prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT deekencoreyr prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial
AT smithericf prospectivemulticentertrialofalongtermbioabsorbablemeshwithsepratechnologyincohortofchallenginglaparoscopicventralorincisionalherniarepairsatlastrial